Skip to content

Comparison of SCS and PMR in Patients With Refractory Angina Pectoris

An Open Single-Centre Parallel Randomised Trial of Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Revascularisation (PMR) in Patients With Refractory Angina Pectoris

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00157742
Enrollment
66
Registered
2005-09-12
Start date
2000-09-30
Completion date
2007-01-31
Last updated
2005-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angina Pectoris

Keywords

Angina Pectoris, Spinal Cord Stimulation (SCS), Percutaneous Myocardial Revascularisation (PMR), Refractory Angina Pectoris

Brief summary

Randomised trial of Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Laser Revascularisation (PMR) in patients with Refractory Angina Pectoris. Hypothesis: difference in exercise tolerance at 12 months between SCS and PMR

Detailed description

The purpose of this open, parallel, single-center prospective, randomised controlled trial is to compare two treatments: Spinal Cord Stimulation (SCS) and Percutaneous Myocardial Laser Revascularisation (PMR) and assess their use and longer term effect in patients with Refractory Angina Pectoris.

Interventions

PROCEDUREPercutaneous Myocardial Laser Revascularisation (PMR)

Sponsors

Medtronic
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient limiting angina (CCS III or IV) despite maximally tolerated medical therapy * Documented coronary artery disease (within the last 9 months prior baseline), which is unsuitable for conventional revascularisation techniques * Patient has documented reversible ischemia on nuclear scan (Tc-99 sestamibi) * Patient is limited in daily activities, primarily exercice capability, by their angina pain * Age 18 or older * Patient must understand the therapy and give informed consent * Patient must be available for appropriate follow-up times for length of Study * Non pregnant woman

Exclusion criteria

* Not candidate for surgical implantation of SCS and/or not for PMR and/or unable to use SCS device appropriately for treatment * Patient who has had one or more major cardiac events within 2 months * Patient with myocardial wall thickness\< 8 mm in the ischaemic area to be treated as verified by echocardiography * Patient with extensive peripheral vascular disease that precludes vascular access required for PMR * Patient on intravenous therapy to control their symptoms * Patient who is unlikely to survive for more than 12 months due to non cardiac condition e.g.malignancy * patient who has other diseases that are considered of greater clinical significance than the angina pectoris that would impact the ability of the clinician to adequately assess the incremental effects of the trial treatment * Patient with ejection fraction of less than 30 % as verified by echocardiography * Patient with cause of angina other than coronary artery disease (e.g. syndrome X patient) * Patient who are unable to perform treadmill exercice test per protocol * Patient who was previously enrolled in this study, or is currently in another clinical study, which will interfere with this protocol * Patient who has has SCS , a TMLR or PMR procedure in the past * Patient with an implanted pacemaker or defibrillator * Patient who has medical conditions which may require Magnetic resonance Imaging (MRI) * Patient with history of dementia or other persisting mental disorders significantly interfering with ability to cooperate or comply with the requirements of the study or comprehend informed consent * Patient with history of Alcohol og Drug abuse

Design outcomes

Primary

MeasureTime frame
Improvement in total exercice time following SCS compared to PMR at 12 months

Secondary

MeasureTime frame
Morbidity/Mortality
Quality of life
Medication consumption
Angina measured by the CCS class and the patients subjectives observations
Myocardial ischemia during exercise treadmill testing
Safety profiles
Difference in myocardial perfusion scanning

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026